ORGO Q2 2020 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$338M

Q2 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$69M+6.2% YoY

Gross Profit

$49M70.9% margin

Operating Income

-$2M-3.3% margin

Net Income

-$5M-7.5% margin

EPS (Diluted)

$-0.05

QoQ Revenue Growth

+11.7%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$12M

Stock-Based Comp.

$469,000

Balance Sheet

Total Assets

$216M

Total Liabilities

$181M

Stockholders' Equity

$36M

Cash & Equivalents

$40M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$69M	$65M	+6.2%
Gross Profit	$49M	$46M	+7.5%
Operating Income	-$2M	-$7M	+69.2%
Net Income	-$5M	-$10M	+46.5%

Revenue Segments

Advanced Wound care

$60M87%

Surgical and Sports Medicine

$9M13%